Skip to content
Catalyst

OutcomesOutcome

Kupperman Menopausal Index total score

1 finding from 1 compound ↓reported in points (total index)

Kupperman Menopausal Index total score

1 finding · 1 compound · by evidence strength. No dose is advised.

Fig. 2 Kupperman Menopausal Index total score1 compound Selected Kupperman Menopausal Index total score · centre
×1.60
Labels
Measured outcomeInspector

Kupperman Menopausal Index total score

Findings drawn, by strength

1finding · 1 compound

  • Very limited1
Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

Compound lowersFindingsStrongest
1
Very limited

Not pooled · no summary effect · point at a mark · Tab, then the arrow keys

Reported to move it1 finding

  1. Schisandra chinensisMoved: lowersEvidence: Very limitedPaper: PMID 277638022016
    Who
    Women aged 40 to 70 years complaining of menopausal symptoms on the Kupperman Index; 41 eligible, 36 completed (18 per group); group-by-time analysis over the 12-week follow-up
    Dose studied
    treatment for 6 weeks, followed for 12 weeks; dose not stated in the abstract

    Total KI scores were significantly lower in the BMO-30 group than in the placebo group when evaluated with respect to group and time (p = 0.042).”

    Quoted verbatim from A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms.RCTPermalink

How it is measured

Total score of the Kupperman Menopausal Index (also Kupperman Menopause Index, KMI), the clinician-scored index summing weighted severity ratings of menopausal symptoms (hot flushes and sweating weighted highest, then paraesthesia, insomnia, nervousness, melancholia, vertigo, weakness, arthralgia and myalgia, headache, palpitations, formication) into one total (higher is worse). The version used (11-item original or a modified item set) and the visit at which it was scored are recorded with each finding.

Papers about it

As an endpoint1

Show the paperHide the paper
  • A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms.

    Climacteric2016PMID 27763802Via: named in the paper, as read